Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 10577344
Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins
granted -
US 10577631
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10578608
Tools to detect, track and target cancer cells in vivo
granted -
US 10576145
CD200 inhibitors and methods of use thereof
granted -
US 10576096
Tumor-selective combination therapy
granted -
US 10576079
Multi-drug therapies for tuberculosis treatment
granted -
US 10570419
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10568913
Method for generating mature Ξ²-like cells
granted -
US 10568831
Method to enhance swallowing safety and appeal of beverages for treating dysphagia based on rheological and sensory parameters
granted -
US 10570382
Transposase polypeptides and uses thereof
granted -
US 10568963
Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles
granted -
US 10568844
RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules
granted -
US 10570418
Methods and compositions for RNA-directed target DNA modification
granted -
US 10570186
Chimeric antigen receptors (CAR) to selectively target protein complexes
granted -
US 10570401
Compositions and method for destabilizing, altering, and dispersing biofilms
granted -
US 10569067
Controlled release nanoparticulate matter delivery system
granted -
US 10568828
Peptide having hair growth-promoting activity and use thereof
granted -
US 10570124
Deoxycytidine kinase binding compounds
granted -
US 10570183
Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
granted -
US 10561763
Oxygen generating biomaterial
granted -
US 10563227
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10563094
Coatings containing polymer modified enzyme for stable self-cleaning of organic stains
granted -
US 10562941
Pneumolysin mutants and methods of use thereof
granted -
US 10563204
Methods of treating cancer harboring hemizygous loss of TP53
granted -
US 10562975
CD6 antibody for treatment of T-cell mediated diseases or disorders
granted -
US 10561670
Compositions comprising acidic extracts of mastic gum
granted -
US 10562849
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
granted -
US 10562886
Anti-cancer compounds
granted -
US 10562839
Medium chain fatty acid esters of Ξ²-hydroxybutyrate and butanediol and compositions and methods for using same
granted -
US 10562938
Theragnostic particles
granted -
US 10557850
Anti-CXCR1 compositions and methods
granted -
US 10556021
Nanocarriers for drug delivery
granted -
US 10555964
Composition and method for promoting reduction of heat stress in animals
granted -
US 10556892
Piperazinyl methanone NAAA inhibitors
granted -
US 10556875
Bis-diazeniumdiolate compounds as anti-cancer agents
granted -
US 10556860
hTERT modulators and methods of use
granted -
US 10550157
Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
granted -
US 10548979
Light-activated compositions and methods using the same
granted -
US 10550407
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10553318
Individual and cohort pharmacological phenotype prediction platform
granted -
US 10550156
Ang (1-7) derivative oligopeptides and methods for using and producing the same
granted -
US 10548962
Use of the salmonella SPP type III secretion proteins as a protective vaccination
granted -
US 10550163
Peptide fragments of netrin-1 and compositions and methods thereof
granted -
US 10550195
Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
granted -
US 10544467
Solid tumor methylation markers and uses thereof
granted -
US 10543337
Nitric oxide delivery devices
granted -
US 10543283
Intranasal administration of guanidinylated aminoglycosides
granted -
US 10544113
Thiazolidinone compounds and use thereof
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory